CTGF levels were significantly higher at 3 months post-LTx in patients who later developed RAS compared to stable LTx recipients (p=0.025), while there was no significant difference with patients who later developed BOS (p=0.28) (Figure 7A). Here, CCN2 is linked to Buschke-Ollendorff syndrome.